• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Supernus Pharmaceuticals (SUPN) Could Be 24% Undervalued If Its CNS Pipeline Delivers

    Simply Wall St·07/22/2026 14:24:53
    语音播报

    Recent Share Performance and Business Snapshot

    Supernus Pharmaceuticals (SUPN) has drawn investor attention after a recent move in its share price, with the stock up 0.9% over the past day and 2.6% over the past week.

    Over the past month, Supernus Pharmaceuticals is up 7.9%. However, the stock is down 4.8% over the past 3 months and down 3.2% year to date, while the 1 year total return stands at 46.5%.

    See our latest analysis for Supernus Pharmaceuticals.

    The recent 1 month share price return of 7.9% for Supernus Pharmaceuticals comes after a weaker 3 month patch, while the 1 year total shareholder return of 46.5% points to momentum that has built over a longer horizon despite short term pullbacks.

    If you are comparing Supernus with other opportunities in the market, it may also be worth scanning companies in AI infrastructure, where demand for computing power and data centers is reshaping parts of the tech and chip ecosystem through the 54 AI infrastructure stocks

    Given Supernus Pharmaceuticals' recent gains, a 32.7% discount to the average analyst target and a very large intrinsic value discount raise a sharper issue: is the market sensibly cautious or mispricing the stock's risks and prospects?

    Most Popular Narrative: 23.8% Undervalued

    Compared with Supernus Pharmaceuticals' last close at $47.87, the most widely followed narrative pegs fair value at $62.83. This implies a meaningful gap that hinges on how its central nervous system portfolio and pipeline play out over time.

    Deep pipeline progress, advancements in late stage candidates like SPN-820 (major depressive disorder) and SPN-443 (next gen ADHD/CNS disorders), support future earnings and revenue growth through differentiated therapies with potentially larger addressable markets.

    Read the complete narrative.

    Curious what kind of revenue ramp, margin rebuild, and profit multiple are baked into that gap between the share price and fair value? The narrative leans on ambitious earnings acceleration, a richer mix from key CNS drugs, and a valuation multiple more commonly seen in higher growth sectors. Want to see exactly how those moving parts stack up against each other and what needs to go right for that view to hold?

    Result: Fair Value of $62.83 (UNDERVALUED)

    Have a read of the narrative in full and understand what's behind the forecasts.

    However, there are still clear pressure points for Supernus Pharmaceuticals, including rising SG&A and R&D costs, as well as heavy reliance on Qelbree and GOCOVRI for a large share of net sales.

    Find out about the key risks to this Supernus Pharmaceuticals narrative.

    Next Steps

    That mix of optimism and caution around Supernus Pharmaceuticals can pull you in both directions, so take a closer look at the underlying data now and decide where you stand, starting with the 4 key rewards.

    Looking for more investment ideas beyond Supernus Pharmaceuticals?

    If Supernus Pharmaceuticals has sharpened your interest in stock research, do not stop here, use targeted screens to uncover companies that better match your risk and return preferences.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.